Table 1 Rifampicin susceptibilities in correlation with the REBA MTB-Rifa® assay on clinical isolates and sputum samples
Phenotypic DST | Sensitivity | Specificity | |||
|---|---|---|---|---|---|
RIF susceptible | RIF resistant | ||||
Clinical isolates | REBA MTB-Rifa® Assay No mutations in RRDR* | 277 | 4 | 98.1% (211/215) | 100% (277/277) |
REBA MTB-Rifa® Assay Mutations in RRDR* | 0 | 211 | |||
Sputum samples | REBA MTB-Rifa® Assay No mutations in RRDR* | 132 | 0 | 100% (96/96) | 100% (132/132) |
REBA MTB-Rifa® Assay Mutations in RRDR* | 0 | 96 | |||